Refine by
Therapies And Technologies In Clinical Articles & Analysis
188 news found
(“Hemostemix” or the “Company”) (TSXV: HEM, OTCQB: HMTXF; FSE:2VF0), the leading autologous (patient’s own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom ...
Yang, L., et al (2024) introduces LungVis 1.0, an AI-driven imaging platform integrating light sheet fluorescence microscopy (LSFM) and deep learning for mapping nanoparticle (NP) deposition across murine lungs. The research highlights the advantages of aerosol-based delivery methods over traditional liquid-based approaches, emphasizing the uniformity of NP deposition in distal alveolar ...
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage development ViGeneron GmbH, a next-generation gene therapy company, today announced the ...
The company’s founding team includes highly experienced executives and internationally renowned experts with track records in developing retinal gene therapy programs from discovery to clinical stage: Dr. Caroline Man Xu (Co-founder and CEO), Prof. ...
On the other hand, non-viral vectors have low immunity and can be injected multiple times and produced in large quantities, revealing great potential in clinical gene therapy. Furthermore, common non-viral vector transgene methods include electroporation, calcium phosphate precipitation, and liposomal delivery. ...
ATG-037 is Antengene’s oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD’s anti-PD-1 therapy The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors The study of ATG-037 monotherapy started enrolling patients in Q2 2022 and will ...
By identifying which patients will not respond to HMA, clinicians can consider other options such as a combination therapy or a clinical trial.” Biosimulation of MDS using differentiation scoring was able to identify patients with minimal benefits from HMA for whom an alternative strategy at the outset of treatment could offer a very meaningful chance to ...
Eikonoklastes Therapeutics, a preclinical biotech company developing treatments for today’s most challenging diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into ...
Further to the announcement of the exclusive option to license the CORE-NK platform released on 21 November 2022, at the request of the ASX, Chimeric Therapeutics (ASX: CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, provides additional information regarding an exclusive license agreement with Case Western Reserve University (CWRU) for ...
Exclusive global license for CORE NK platform (CHM 0201) executed with Case Western Reserve University in Ohio Initial Phase 1 clinical trial results of the CORE NK platform (CHM 0201) were published demonstrating safety and encouraging activity in blood cancers and solid tumours One patient achieved a complete response that was sustained for over 15 months at time of publication Based on ...
For nearly 16 years, she worked for CureVac, the global biopharmaceutical company and took responsibility as Chief Scientific and Chief Technology Officer. Her revolutionary work has supported multiple clinical trials with cancer therapies, prophylactic vaccines, and development of antibody therapies. ...
ByArdigen
In this webinar, I look forward to exploring current and new strategies for optimising the upstream AAV vector production process, a vital first step towards advancing gene therapies to meet clinical and commercial yields.” Dr. Jean-Simon Diallo, CEO of Virica Biotech. ...
DR CHENG BOON, ONCOLOGIST IN THE PRIVATE SECTOR AND THE NHS AS WELL AS ACTING AS ONCODNA UK MEDIAL DIRECTOR COMMENTED: “In my view, this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP* for the purpose of routine next generation sequencing. This unique public-private ...
Tavros leverages its functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need and identify novel clinical positioning strategies for existing molecules. ...
ByBayer AG
Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced further collaboration for their manufacturing partnership to include clinical stage plasmid DNA production to support Ray Therapeutics’ lead optogenetics ...
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer antigen 1 (KK-LC-1) expressing malignancies, ...
Myrtelle Inc., (Myrtelle), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Myrtelle’s novel gene ...
The company partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized ...
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that company leadership members will be making presentations and taking one-on-one meetings at three upcoming investor relations conferences. Jefferies Cell & Genetic Medicine Summit Friday, September 30, 10:00-10:25 a.m. ET Presenter: Christina Perry, Senior Vice President and Head, ...
Enables gene therapy clients to accelerate AAV manufacturing with seamless incorporation into the Company’s HEK 293 platform suspension process with access to end-to-end capabilities New offerings of Research-Grade and GMP-Pathway expedite Phase 1/2 clinical trial timelines, with GMP-Grade available in 2023 Data to support Company’s plasmid production is being presented at ...